PE20110565A1 - Metodo de identificacion de factores de riesgo de la enfermedad - Google Patents
Metodo de identificacion de factores de riesgo de la enfermedadInfo
- Publication number
- PE20110565A1 PE20110565A1 PE2011000157A PE2011000157A PE20110565A1 PE 20110565 A1 PE20110565 A1 PE 20110565A1 PE 2011000157 A PE2011000157 A PE 2011000157A PE 2011000157 A PE2011000157 A PE 2011000157A PE 20110565 A1 PE20110565 A1 PE 20110565A1
- Authority
- PE
- Peru
- Prior art keywords
- disease
- affected
- subjects
- genetic
- interest
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
Abstract
SE REFIERE A UN PROCEDIMIENTO PARA IDENTIFICAR UNA VARIANTE GENETICA QUE ESTA ASOCIADA CON EL DESARROLLO DE UNA ENFERMEDAD SELECCIONADA ENTRE DIABETES MLLITUS TIPO II, PARKINSON, ALZHEIMER, ENTRE OTROS, QUE COMPRENDE: A) DETERMINAR LAS MUESTRAS BIOLOGICAS QUE CONTIENEN EL ADN LAS SECUENCIAS DE NUCLEOTIDOS PORTADAS POR UNA PLURALIDAD DE SUJETOS EN UN LUGAR GENETICO DE INTERES, DONDE DICHOS SUJETOS INCLUYEN LOS AFECTADOS COMO LOS NO AFECTADOS POR UNA ENFERMEDAD DE INTERES; B) REALIZAR EL ANALISIS DE ALINEACION DE SECUENCIAS MULTIPLES PARA IDENTIFICAR LAS VARIANTES GENETICAS; C) MAPEAR DICHAS VARIANTES GENETICAS PARA CONSTRUIR UN ARBOL FILOGENETICO DE DICHOS SUJETOS; D) EXAMINAR LAS VARIANTES GENETICAS REPRESENTADAS COMO RAMAS EN DICHO ARBOL Y DETERMINAR LA PROPORCION DE SUJETOS AFECTADOS Y NO AFECTADOS; E) IDENTIFICAR UNA VARIANTE GENETICA ASOCIADA CON EL DESARROLLO DE DICHO PADECIMIENTO DE INTERES
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8820308P | 2008-08-12 | 2008-08-12 | |
US18667309P | 2009-06-12 | 2009-06-12 | |
US22464709P | 2009-07-10 | 2009-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110565A1 true PE20110565A1 (es) | 2011-09-02 |
Family
ID=41669605
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011000157A PE20110565A1 (es) | 2008-08-12 | 2009-08-11 | Metodo de identificacion de factores de riesgo de la enfermedad |
PE2015002280A PE20151924A1 (es) | 2008-08-12 | 2009-08-11 | Metodo de identificacion de factores de riesgo de la enfermedad |
PE2015000030A PE20150362A1 (es) | 2008-08-12 | 2009-08-11 | Metodo de identificacion de factores de riesgo de la enfermedad |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015002280A PE20151924A1 (es) | 2008-08-12 | 2009-08-11 | Metodo de identificacion de factores de riesgo de la enfermedad |
PE2015000030A PE20150362A1 (es) | 2008-08-12 | 2009-08-11 | Metodo de identificacion de factores de riesgo de la enfermedad |
Country Status (32)
Country | Link |
---|---|
US (4) | US8815508B2 (es) |
EP (2) | EP2324126B1 (es) |
JP (4) | JP5833922B2 (es) |
KR (3) | KR20180053432A (es) |
CN (3) | CN102177436B (es) |
AU (3) | AU2009282114B2 (es) |
BR (1) | BRPI0917948A2 (es) |
CA (1) | CA2735578C (es) |
CL (1) | CL2011000298A1 (es) |
CO (1) | CO6351823A2 (es) |
CY (1) | CY1115412T1 (es) |
DK (1) | DK2324126T3 (es) |
DO (1) | DOP2011000052A (es) |
EA (1) | EA021399B1 (es) |
ES (1) | ES2463766T3 (es) |
GE (1) | GEP20146107B (es) |
HK (1) | HK1153511A1 (es) |
HR (1) | HRP20140709T1 (es) |
IL (2) | IL211140A (es) |
MA (1) | MA32619B1 (es) |
ME (1) | ME01898B (es) |
MX (1) | MX2011001671A (es) |
NZ (3) | NZ591107A (es) |
PE (3) | PE20110565A1 (es) |
PL (1) | PL2324126T3 (es) |
PT (1) | PT2324126E (es) |
RS (1) | RS53383B (es) |
SG (1) | SG193793A1 (es) |
SI (1) | SI2324126T1 (es) |
SM (1) | SMT201400088B (es) |
WO (1) | WO2010019550A2 (es) |
ZA (1) | ZA201101095B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA021399B1 (ru) * | 2008-08-12 | 2015-06-30 | Зинфандел Фармасьютикалз, Инк. | Способ идентификации факторов риска заболеваний |
US8846315B2 (en) * | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
KR101952965B1 (ko) | 2010-05-25 | 2019-02-27 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Bambam:고처리율 서열분석 데이터의 병렬 비교 분석 |
US9646134B2 (en) * | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
AU2011354696B2 (en) * | 2011-01-10 | 2015-03-05 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
KR20180050420A (ko) | 2011-01-10 | 2018-05-14 | 진판델 파마슈티컬스 인코포레이티드 | 알츠하이머 병 치료를 위한 방법 및 약품 |
AU2013204020B2 (en) * | 2011-01-10 | 2016-03-31 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
US20120231457A1 (en) * | 2011-03-10 | 2012-09-13 | Nikolaos Tezapsidis | Compositions and methods for assessing a genetic risk of developing late-onset alzheimer's disease (load) |
US8718950B2 (en) | 2011-07-08 | 2014-05-06 | The Medical College Of Wisconsin, Inc. | Methods and apparatus for identification of disease associated mutations |
US20130080182A1 (en) * | 2011-09-26 | 2013-03-28 | Athleticode Inc. | Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury |
JP2015505314A (ja) * | 2012-01-09 | 2015-02-19 | 武田薬品工業株式会社 | アルツハイマー病を治療する方法及び医薬品 |
GB201209689D0 (en) * | 2012-05-31 | 2012-07-18 | Imp Innovations Ltd | Methods |
US10586612B2 (en) | 2013-03-01 | 2020-03-10 | Actx, Inc. | Cloud-like medical-information service |
JPWO2015174544A1 (ja) * | 2014-05-16 | 2017-04-20 | 国立研究開発法人国立精神・神経医療研究センター | 精神疾患判定マーカー |
WO2017015543A1 (en) | 2015-07-23 | 2017-01-26 | Asuragen, Inc. | Methods, compositions, kits, and uses for analysis of nucleic acids comprising repeating a/t-rich segments |
JP7475811B2 (ja) * | 2016-05-20 | 2024-04-30 | シーダーズ―シナイ メディカル センター | 遺伝子に基づく炎症性腸疾患の診断 |
CN105969885A (zh) * | 2016-06-24 | 2016-09-28 | 江苏雄鸣医药科技有限公司 | 一种阿尔兹海默症的基因诊断试剂盒 |
WO2018132755A1 (en) * | 2017-01-12 | 2018-07-19 | Duke University | Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease |
WO2018175581A1 (en) * | 2017-03-21 | 2018-09-27 | The Jackson Laboratory | A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF |
CA3071626A1 (en) * | 2017-07-31 | 2019-02-07 | Quest Diagnostics Investments Llc | Apolipoprotein e isotype detection by mass spectrometry |
WO2019086555A1 (en) * | 2017-10-31 | 2019-05-09 | Ge Healthcare Limited | Medical system for diagnosing cognitive disease pathology and/or outcome |
US20200357523A1 (en) * | 2018-01-31 | 2020-11-12 | Curelator, Inc. | Early Feedback of Disease Factors to Improve Patient Quality of Life, Engagement and Persistence |
KR102303638B1 (ko) * | 2018-04-13 | 2021-09-23 | 사회복지법인 삼성생명공익재단 | 알츠하이머성 치매가 발병될 가능성 평가방법 |
US20210230696A1 (en) | 2018-05-07 | 2021-07-29 | Biotx.Ai Gmbh | Method for predicting the risk of late-onset alzheimer's diseases |
CA3100897A1 (en) * | 2018-05-18 | 2019-11-21 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
EP3626835A1 (en) * | 2018-09-18 | 2020-03-25 | Sistemas Genómicos, S.L. | Method for genotypically identifying both alleles of at least one locus of a subject's hla gene |
KR102127903B1 (ko) * | 2019-01-29 | 2020-06-29 | 연세대학교 산학협력단 | 염증성 호흡기 질환의 진단용 바이오마커 |
CA3141888A1 (en) * | 2019-05-30 | 2020-12-03 | The University Of Newcastle | A method of treatment or prophylaxis |
CN111187825A (zh) * | 2020-01-15 | 2020-05-22 | 丁玎 | 阿尔兹海默症的tomm40基因及apoe基因的易感位点的检测方法及试剂盒 |
CN111593107A (zh) * | 2020-01-15 | 2020-08-28 | 丁玎 | 阿尔兹海默症易感位点rs10119与rs71352238的检测方法及试剂盒 |
KR102535235B1 (ko) * | 2020-11-25 | 2023-05-26 | 서울대학교산학협력단 | 알츠하이머병 발병 위험도 예측을 위한 단일염기다형성 마커 및 이의 용도 |
RU2757522C1 (ru) * | 2021-06-02 | 2021-10-18 | Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) | СПОСОБ ПРОГНОЗИРОВАНИЯ РАЗВИТИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 1 и 2 ТИПА (варианты) |
KR20230150497A (ko) * | 2022-04-22 | 2023-10-31 | 사회복지법인 삼성생명공익재단 | 유럽-동아시아인 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법 |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US663780A (en) * | 1898-09-09 | 1900-12-11 | Wheeler & Wilson Mfg Co | Trimming attachment for sewing-machines. |
US4302204A (en) | 1979-07-02 | 1981-11-24 | The Board Of Trustees Of Leland Stanford Junior University | Transfer and detection of nucleic acids |
US4358535A (en) | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
FI63596C (fi) | 1981-10-16 | 1983-07-11 | Orion Yhtymae Oy | Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser |
US4994373A (en) | 1983-01-27 | 1991-02-19 | Enzo Biochem, Inc. | Method and structures employing chemically-labelled polynucleotide probes |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US6060237A (en) * | 1985-02-26 | 2000-05-09 | Biostar, Inc. | Devices and methods for optical detection of nucleic acid hybridization |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5112460A (en) * | 1986-10-21 | 1992-05-12 | Northeastern University | High performance microcapillary gel electrophoresis |
ATE186724T1 (de) | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
US5595883A (en) * | 1990-06-01 | 1997-01-21 | E. R. Squibb & Sons, Inc. | Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid |
US5171750A (en) | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
TW263504B (es) | 1991-10-03 | 1995-11-21 | Pfizer | |
US5326770A (en) * | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
NZ248573A (en) * | 1992-09-10 | 1996-02-27 | Lilly Co Eli | 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions |
EP0625212B1 (en) | 1992-10-13 | 2004-03-24 | Duke University | Methods of detecting alzheimer's disease |
TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
JPH09176162A (ja) | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
US6128587A (en) | 1997-01-14 | 2000-10-03 | The Regents Of The University Of California | Method and apparatus using Bayesian subfamily identification for sequence analysis |
US5904824A (en) * | 1997-03-07 | 1999-05-18 | Beckman Instruments, Inc. | Microfluidic electrophoresis device |
JP2001514663A (ja) * | 1997-03-12 | 2001-09-11 | エスモンド,ロバート ダブリュー. | アルツハイマー病を処置または予防するための方法 |
DE69809827D1 (de) | 1997-03-31 | 2003-01-16 | Korea Res Inst Chem Tech | Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung |
DE69834508T2 (de) * | 1997-11-19 | 2006-11-23 | Takeda Pharmaceutical Co. Ltd. | Apoptoseinhibitoren |
US6964868B1 (en) | 1998-01-28 | 2005-11-15 | Nuvelo, Inc. | Human genes and gene expression products II |
US7122373B1 (en) | 1998-05-14 | 2006-10-17 | Nuvelo, Inc. | Human genes and gene expression products V |
US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
JP2002518022A (ja) | 1998-06-16 | 2002-06-25 | ノヴァ モレキュラー インク. | Bche遺伝子型の決定による神経疾患の治療法 |
WO2000020634A1 (en) | 1998-10-01 | 2000-04-13 | Nova Molecular, Inc. | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
US6291182B1 (en) * | 1998-11-10 | 2001-09-18 | Genset | Methods, software and apparati for identifying genomic regions harboring a gene associated with a detectable trait |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
CN1078616C (zh) * | 1998-12-16 | 2002-01-30 | 中国科学院上海生命科学研究中心 | 一种检测样品中是否存在老年痴呆病基因的方法和试剂盒 |
JP2000273040A (ja) * | 1999-01-19 | 2000-10-03 | Sankyo Co Ltd | トログリタゾンを含有するアポトーシス抑制剤 |
US6401043B1 (en) | 1999-04-26 | 2002-06-04 | Variagenics, Inc. | Variance scanning method for identifying gene sequence variances |
WO2000066102A2 (en) | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
US6573049B1 (en) | 1999-07-26 | 2003-06-03 | Nuvelo, Inc. | Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease |
DE19936719A1 (de) * | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte 1,5-Dihydropyrrol-2-on-Derivate |
US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
AR030920A1 (es) | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6532467B1 (en) | 2000-04-10 | 2003-03-11 | Sas Institute Inc. | Method for selecting node variables in a binary decision tree structure |
US6432985B2 (en) | 2000-04-25 | 2002-08-13 | Hoffmann-La Roche Inc. | Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists |
US20040122091A1 (en) * | 2000-10-11 | 2004-06-24 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
WO2002030884A2 (en) | 2000-10-11 | 2002-04-18 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
US7304093B2 (en) * | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
CN1479721A (zh) * | 2000-10-11 | 2004-03-03 | ͨ��ҽ�ƹ�˾ | 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物 |
MXPA03003020A (es) * | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de cetona y composiciones para el control del colesterol y usos relacionados. |
US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
JP4162486B2 (ja) | 2000-11-24 | 2008-10-08 | ヴァスキュラー バイオジェニックス リミテッド | アテローム性動脈硬化を防止および処置するための規定された酸化型リン脂質を用いる方法およびそのような酸化型リン脂質を含有する組成物 |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US6495335B2 (en) | 2000-12-07 | 2002-12-17 | Mario Chojkier | Compositions and methods for diagnosing alzheimer's disease |
DE10132725A1 (de) | 2001-07-05 | 2006-08-03 | Grünenthal GmbH | Substituierte γ-Lactonverbindungen |
US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
US20040204502A1 (en) * | 2001-10-11 | 2004-10-14 | Dasseux Jean-Louis Henri | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US20050020694A1 (en) | 2001-10-11 | 2005-01-27 | Dasseux Jean-Louis Henri | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
US6828462B2 (en) | 2001-11-07 | 2004-12-07 | Merz Pharma Gmbh & Co. Kgaa | Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
US7132244B2 (en) * | 2001-11-21 | 2006-11-07 | Syn X Pharma, Inc. | Betaine/GABA transport protein biopolymer marker indicative of insulin resistance |
US7135297B2 (en) | 2001-11-23 | 2006-11-14 | Nanogen Inc. | Protein biopolymer markers indicative of insulin resistance |
US7052849B2 (en) | 2001-11-23 | 2006-05-30 | Syn X Pharma, Inc. | Protein biopolymer markers predictive of insulin resistance |
US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
WO2004005510A1 (ja) | 2002-07-05 | 2004-01-15 | Shionogi & Co., Ltd. | 新規Nogo受容体様ポリペプチドおよびそのDNA |
US20040265849A1 (en) * | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
CN1753662A (zh) * | 2002-12-24 | 2006-03-29 | 神经化学(国际)有限公司 | 用于治疗β-淀粉状蛋白相关疾病的治疗制剂 |
JP2006519440A (ja) * | 2003-02-14 | 2006-08-24 | インタージェネティックス インコーポレイテッド | 疾患の増大リスクの統計学的同定法 |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US20050004179A1 (en) * | 2003-05-22 | 2005-01-06 | Pedersen Ward A. | Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease |
US20070203083A1 (en) | 2003-06-13 | 2007-08-30 | Mootha Vamsi K | Methods Of Regulating Metabolism And Mitochondrial Function |
TW200520745A (en) | 2003-09-19 | 2005-07-01 | Chugai Pharmaceutical Co Ltd | Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors |
JP2007526764A (ja) | 2004-01-22 | 2007-09-20 | ジェネッサンス ファーマシューティカルズ,インコーポレイティド | アルツハイマー病の発症年齢に関連するapoe遺伝子マーカー |
TW200538738A (en) | 2004-02-20 | 2005-12-01 | Univ California | Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity |
WO2006054297A2 (en) | 2004-11-17 | 2006-05-26 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
WO2006083854A2 (en) | 2005-01-31 | 2006-08-10 | Perlegen Sciences, Inc. | Genetic basis of alzheimer's disease and diagnosis and treatment thereof |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
BRPI0616100A2 (pt) | 2005-09-22 | 2011-06-07 | Sb Pharmco Inc | combinação de rosiglitazona e donepezil para melhoramento da função cognitiva |
WO2007044522A1 (en) | 2005-10-05 | 2007-04-19 | Auburn University | P62 as a risk determinant for metabolic syndrome |
UA96441C2 (ru) | 2006-03-16 | 2011-11-10 | Метаболик Солюшнз Девелопмент Компани | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением |
US20080045582A1 (en) | 2006-05-15 | 2008-02-21 | Issam Zineh | ENA-78 Gene Polymorphisms and Protein Concentrations as Diagnostic and Prognostic Tools |
US8486635B2 (en) | 2006-05-30 | 2013-07-16 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
US7651840B2 (en) * | 2006-07-14 | 2010-01-26 | Celera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
US20080103165A1 (en) | 2006-09-19 | 2008-05-01 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
US20090042849A1 (en) | 2006-12-06 | 2009-02-12 | Yochai Birnbaum | Phosphorylation of 5-lipoxygenase at ser523 and uses thereof |
US7794937B2 (en) | 2006-12-22 | 2010-09-14 | Quest Diagnostics Investments Incorporated | Cystic fibrosis transmembrane conductance regulator gene mutations |
GB0702537D0 (en) | 2007-02-12 | 2007-03-21 | Leuven K U Res & Dev | Treatment for excessive adiposity |
US20080286876A1 (en) | 2007-05-14 | 2008-11-20 | Chissoe Stephanie | GENES ASSOCIATED WITH ALZHEIMER'S DISEASE - Hltdip |
CA2688293A1 (en) | 2007-05-25 | 2008-12-04 | Childrens's Medical Center Corporation | Dietary formulations and methods for treatment of inflammation and other disorders |
TW200914006A (en) | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
US8846315B2 (en) * | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
EA021399B1 (ru) | 2008-08-12 | 2015-06-30 | Зинфандел Фармасьютикалз, Инк. | Способ идентификации факторов риска заболеваний |
US20100136584A1 (en) | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
WO2010033913A1 (en) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
BRPI0919882A8 (pt) | 2008-10-30 | 2017-09-19 | Caris Life Sciences Luxembourg Holdings | Métodos para avaliar padrões de rna |
WO2010056337A2 (en) | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
EP2367802B1 (en) | 2008-12-12 | 2016-04-20 | Poxel | Tetrahydrotriazine compounds for treating diseases associated with ampk activity |
CA2751227C (en) | 2009-02-02 | 2021-10-26 | Laila Nutraceuticals | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome |
US8865648B2 (en) | 2009-04-23 | 2014-10-21 | Siemens Healthcare Diagnostics Inc. | Monomeric and dimeric forms of adiponectin receptor fragments and methods of use |
AU2010202926B2 (en) | 2009-09-11 | 2016-07-14 | Electrophoretics Limited | Markers and methods relating to the assessment of Alzheimer's disease |
US8574856B2 (en) | 2010-02-10 | 2013-11-05 | Companion Diagnostics Inc. | Methods for determining the efficiency of a therapeutic |
AU2011223789A1 (en) | 2010-03-01 | 2012-09-20 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
KR20180050420A (ko) * | 2011-01-10 | 2018-05-14 | 진판델 파마슈티컬스 인코포레이티드 | 알츠하이머 병 치료를 위한 방법 및 약품 |
-
2009
- 2009-08-11 EA EA201170332A patent/EA021399B1/ru not_active IP Right Cessation
- 2009-08-11 MX MX2011001671A patent/MX2011001671A/es active IP Right Grant
- 2009-08-11 DK DK09807152.5T patent/DK2324126T3/da active
- 2009-08-11 NZ NZ591107A patent/NZ591107A/xx not_active IP Right Cessation
- 2009-08-11 KR KR1020187013536A patent/KR20180053432A/ko not_active Application Discontinuation
- 2009-08-11 SG SG2013061254A patent/SG193793A1/en unknown
- 2009-08-11 PL PL09807152T patent/PL2324126T3/pl unknown
- 2009-08-11 CA CA2735578A patent/CA2735578C/en not_active Expired - Fee Related
- 2009-08-11 NZ NZ619895A patent/NZ619895A/en not_active IP Right Cessation
- 2009-08-11 SI SI200930940T patent/SI2324126T1/sl unknown
- 2009-08-11 EP EP09807152.5A patent/EP2324126B1/en active Active
- 2009-08-11 PE PE2011000157A patent/PE20110565A1/es not_active Application Discontinuation
- 2009-08-11 PT PT98071525T patent/PT2324126E/pt unknown
- 2009-08-11 CN CN200980140279.0A patent/CN102177436B/zh not_active Expired - Fee Related
- 2009-08-11 PE PE2015002280A patent/PE20151924A1/es unknown
- 2009-08-11 ME MEP-2014-70A patent/ME01898B/me unknown
- 2009-08-11 AU AU2009282114A patent/AU2009282114B2/en not_active Ceased
- 2009-08-11 CN CN201510173806.5A patent/CN104805198B/zh not_active Expired - Fee Related
- 2009-08-11 WO PCT/US2009/053373 patent/WO2010019550A2/en active Application Filing
- 2009-08-11 EP EP14165474.9A patent/EP2789695B1/en active Active
- 2009-08-11 KR KR1020167030021A patent/KR20160127181A/ko active Search and Examination
- 2009-08-11 NZ NZ710443A patent/NZ710443A/en not_active IP Right Cessation
- 2009-08-11 JP JP2011523086A patent/JP5833922B2/ja active Active
- 2009-08-11 KR KR1020117005712A patent/KR101729340B1/ko active IP Right Grant
- 2009-08-11 GE GEAP200912125A patent/GEP20146107B/en unknown
- 2009-08-11 BR BRPI0917948A patent/BRPI0917948A2/pt not_active Application Discontinuation
- 2009-08-11 US US13/058,724 patent/US8815508B2/en active Active
- 2009-08-11 RS RS20140335A patent/RS53383B/en unknown
- 2009-08-11 ES ES09807152.5T patent/ES2463766T3/es active Active
- 2009-08-11 PE PE2015000030A patent/PE20150362A1/es not_active Application Discontinuation
- 2009-08-11 CN CN201510007052.6A patent/CN104611421B/zh not_active Expired - Fee Related
-
2011
- 2011-02-09 IL IL211140A patent/IL211140A/en active IP Right Grant
- 2011-02-10 ZA ZA2011/01095A patent/ZA201101095B/en unknown
- 2011-02-11 DO DO2011000052A patent/DOP2011000052A/es unknown
- 2011-02-11 CL CL2011000298A patent/CL2011000298A1/es unknown
- 2011-03-07 MA MA33680A patent/MA32619B1/fr unknown
- 2011-03-09 CO CO11028662A patent/CO6351823A2/es not_active Application Discontinuation
- 2011-07-21 HK HK11107605.9A patent/HK1153511A1/xx not_active IP Right Cessation
-
2014
- 2014-07-09 SM SM201400088T patent/SMT201400088B/xx unknown
- 2014-07-16 US US14/332,867 patent/US20150073025A1/en not_active Abandoned
- 2014-07-22 HR HRP20140709AT patent/HRP20140709T1/hr unknown
- 2014-07-22 CY CY20141100549T patent/CY1115412T1/el unknown
-
2015
- 2015-06-08 IL IL239277A patent/IL239277A0/en unknown
- 2015-10-29 JP JP2015212976A patent/JP2016047058A/ja active Pending
-
2016
- 2016-07-06 AU AU2016204678A patent/AU2016204678B2/en not_active Ceased
-
2017
- 2017-11-10 JP JP2017217336A patent/JP2018075005A/ja active Pending
-
2018
- 2018-04-04 AU AU2018202373A patent/AU2018202373A1/en not_active Abandoned
- 2018-06-28 US US16/021,261 patent/US10865449B2/en active Active
- 2018-12-05 JP JP2018228465A patent/JP6815372B2/ja active Active
-
2020
- 2020-11-13 US US17/097,705 patent/US20210095345A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110565A1 (es) | Metodo de identificacion de factores de riesgo de la enfermedad | |
AR119062A2 (es) | Evento de maíz mon 87411 | |
AR117199A2 (es) | Evento das-40278-9 de aad-1, líneas transgénicas de maíz relacionadas, e identificación evento-específico de las mismas | |
HN2008000346A (es) | Secuencias de nucleotidos que codifican proteinas insecticidas | |
CO6700873A2 (es) | Planta y semilla de soja correspondiente al evento transgenico mon87712 y métodos para su detección. | |
WO2011071923A3 (en) | Multi-sample indexing for multiplex genotyping | |
SG194233A1 (en) | Identification of polynucleotides associated with a sample | |
PE20221408A1 (es) | Nuevas proteinas inhibidoras de insectos | |
DOP2013000296A (es) | Enfermedad tromboembólica | |
BR112013033348A2 (pt) | meios e processos para a determinação de modelos de previsão associados com um fenótipo | |
CL2012002347A1 (es) | Metodo in vitro para el diagnostico de la demencia con cuerpos de lewy (lbd), que comprende determinar en una muestra biológica de un individuo el genotipo de las siguientes alteraciones en el gen de la butirilcolinesterasa o de polimorfismos en desequilibrio de union de los mismos; kit para llevar a cabo dicho método; uso del kit para el diagnóstico de lbd. | |
BR112013025459A2 (pt) | análise de alto rendimento de bordas de transgenes | |
AR101779A2 (es) | Secuencias de nucleótidos msca1 que afectan la fertilidad vegetal masculina y método para usar las mismas | |
BR112015015500A2 (pt) | método para o rastreamento completo de um conjunto de amostras biológicas contendo dna ou rna através da identificação do código de barras molecular durante o fluxo de trabalho de laboratório e kit para coleta de amostras biológicas de dna ou rna | |
MX2018014163A (es) | Composiciones de nucleotido marcados y metodos para el secuenciamiento de acido nucleico. | |
MX2015012319A (es) | Sistemas de instrumento analitico. | |
AR097489A1 (es) | Marcadores de riesgo para cardiovasculopatías en pacientes con nefropatía crónica | |
AR088647A1 (es) | Metodo para reducir el estres abiotico en la planta | |
BR112016023624A2 (pt) | proteínas de antiporte prótons/ açúcar tonoplásticas e uso do mesmo para o aumento da concentração de sacarose de um órgão de plantas para armazenamento de sacarose | |
AR101049A1 (es) | Plantas de brassica que comprenden alelos mutantes de da1 | |
ES2351916B8 (es) | Metodo de identificacion de celulas madre mesenquimales senescentes | |
ATE523588T1 (de) | Polynukleotide zur verbesserung der expression eines interessierenden polynukleotids | |
AR113786A1 (es) | Método para marcar secuencias de ácido nucleicos, composición y uso de la misma | |
ES2442226B1 (es) | Método para la obtención del perfil genético de un individuo mediante el análisis de loci de cromosoma x | |
CR20120583A (es) | Métodos para la identificación de composiciones que alteran la expresión de genes y proteínas en una célula de planta de tipo silvestre |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |